NanoViricides Has Filed its Quarterly Report – Clinical Trials of Broad-Spectrum COVID Drug About to Begin

NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.

Scroll to Top